Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test

Tweet Shares of Exact Sciences (NASDAQ:EXAS) plummeted as much as 30% on heavier than normal trading volumes today after the company released a preliminary analysis of its DeeP-C pivotal trial with its Cologuard colorectal cancer screening test.   The stock recovered somewhat later in the day, closing down $1.14 to $8.84. Exact Sciences’ test, which identifies abnormal [...]

In conversation with Gailina Liew

Tweet As president and COO of GeneNews (TSX:GEN), Gailina Liew established the initial intellectual property strategy and organizational infrastructure for the company over the past dozen years. More recently, she has led the commercialization effort for ColonSentry, a new patient friendly blood test to assess an individual’s current risk of having colorectal cancer. ColonSentry is [...]

GeneNews raises $7.7-million in upsized stock offering

Tweet GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of new common shares for gross proceeds of about $7.7-million, up from the $6-million target announced on Dec. 7 due to strong demand. The offering will result in the issuance of about 86.3 million common shares at a price of nine cents a [...]

GeneNews posts big jump in Q3 revenue and initiates study

Tweet Citing a positive response to the commercial launch of ColonSentry, the world’s first blood test to assess an individual’s current risk for colorectal cancer, by U.S. marketing partner, Enzo Clinical Labs, GeneNews (TSX:GEN) has reported revenue of $157,692 for the third quarter, an increase of 258% from $43,999 for the same period in 2011 [...]

GeneNews to set up Sentinel Center in Shanghai

Tweet GeneNews (TSX:GEN) has entered into a partnership agreement with Shanghai Biochip (SBC), a leading Chinese engineering center for advanced microarray and gene expression profiling technologies. GeneNews and SBC will establish the first Sentinel Centre for Personalized Medicine, based in Shanghai, to co-develop and commercialize additional products based on GeneNews’ proprietary platform technology, the Sentinel [...]

GeneNews partner to expand ColonSentry launch

Tweet GeneNews’ (TSX:GEN) marketing partner, Enzo Clinical Labs, reports that the early interest shown by doctors and patients during the initial launch of ColonSentry in New York and New Jersey has been high and current efforts are focused on increasing lab capacity and an expanded launch. “Accordingly, we believe that the ColonSentry business will start [...]

GeneNews completes rights offering

Tweet GeneNews (TSX:GEN) has completed its previously announced rights offering, issuing 23,224,529 common shares at a price of 11 cents each for gross proceeds of about $2.55 million. The rights offering was fully subscribed with 11,575,301 shares issued under the basic subscription privilege, 10,458,417 shares under an additional subscription privilege, and 1,190,811 shares under a [...]

GeneNews to Present Liver Cancer Data at ASCO 2012

Tweet GeneNews (TSX:GEN) has announced that a poster entitled, “Blood signatures for early liver cancer detection in patients with chronic hepatitis B,” has been selected for presentation at the 2012 annual meeting of the American Society of Clinical Oncology in Chicago from June 1 to 5. President and COO Gailina Liew said that applications of [...]

GeneNews’ first U.S. marketing partner launches ColonSentry

Tweet GeneNews (TSX: GEN) says Enzo Clinical Labs, a division of Enzo Biochem (NYSE:ENZ), has launched ColonSentry, the world’s first blood test to assess an individual’s current risk for colorectal cancer, in the state of New York. “Enzo’s launch of ColonSentry is a significant milestone for the commercialization of GeneNews’ proprietary Sentinel Principle platform technology,” [...]

NY approval of ColonSentry opens door for GeneNews

Tweet Last week’s approval by New York State of GeneNews’ (TSX:GEN) ColonSentry molecular diagnostic test to determine a person’s risk of having colorectal cancer opens the door to the entire U.S. market and other jurisdictions around the world for the simple blood test. “Our lead product has now been approved by the most stringent level [...]

Next Page »